The aim of our study was to assess the frequency and specificity of antibodies to AQP4 in patients with NMO, as well as relevant differential diagnoses, by means of a newly developed radioimmunoprecipitation assay (RIPA). Here, AQP4 is linked to neuromyelitis optica.